ArticleDiscover oncology2025
RRP9 promotes prostate cancer metastasis and epithelial-mesenchymal transition through activation of the AKT/GSK3β/β-Catenin signaling pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytokines IL-6, IL-10, and CCL5 Secreted by Infiltrating B Cells Promote Cell Migration of Human Prostate Cancer Cell Lines.Oncology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ribosomal RNA Processing 9 (RRP9) is a gene associated with ribosomal function, and studies have demonstrated that its expression is aberrantly regulated in various tumor types, correlating with tumor progression. However, the specific role and underlying mechanism of RRP9 in prostate cancer (PCa) remain largely unexplored. In this study, bioinformatics analysis revealed that RRP9 is upregulated in PCa and is significantly associated with poor prognosis and lymph node metastasis. Further experimental data demonstrated that RRP9 knockdown notably inhibited the metastasis, invasion, and epithelial-mesenchymal transition (EMT) of PCa. Conversely, overexpression of RRP9 activated the AKT signaling pathway, resulting in the phosphorylation of GSK3β at Ser9, which in turn prevented β-catenin degradation and promoted cell metastasis, invasion, and EMT. Rescue experiments demonstrated that SC79 effectively reversed the inhibitory effects of RRP9 knockdown on PCa. These findings highlight the potential role of RRP9 in promoting the malignant biological behaviors of PCa, providing new insights and potential therapeutic strategies for the treatment of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.